Endocrine Abstracts

Background: In the last decade, immunotherapy proved to be the frontline in the fight against cancer in a rocketing area of cancer types. Boosting the body’s inherent immune system, a new set of toxicities raised, labeled as immune-related adverse events (irAEs). Endocrine disorders, particularly thyroid dysfunctions, are by far the most frequent irAEs during immune checkpoint inhibitors (ICIs) therapy. New research data explored their predictive impact in cancer patients...